Segall Bryant & Hamill’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-41,558
Closed -$1.69M 591
2025
Q4
$1.69M Sell
41,558
-88
-0.2% -$3.83K 0.02% 456
2025
Q3
$1.96M Buy
41,646
+14,831
+55% +$769K 0.03% 435
2025
Q2
$1.4M Buy
+26,815
New +$1.47M 0.02% 476
2024
Q1
Sell
-77,686
Closed -$8.51M 307
2023
Q4
$8.51M Buy
77,686
+252
+0.3% +$26.1K 0.16% 208
2023
Q3
$7.81M Sell
77,434
-491
-0.6% -$56.4K 0.09% 254
2023
Q2
$10.6M Buy
77,925
+361
+0.5% +$44.1K 0.11% 226
2023
Q1
$8.05M Sell
77,564
-49,129
-39% -$4.75M 0.09% 258
2022
Q4
$11.2M Buy
126,693
+8,479
+7% +$704K 0.13% 203
2022
Q3
$9.48M Buy
118,214
+17,542
+17% +$1.65M 0.11% 215
2022
Q2
$9.64M Buy
100,672
+29,910
+42% +$3.59M 0.11% 207
2022
Q1
$10.5M Buy
70,762
+169
+0.2% +$23.6K 0.1% 210
2021
Q4
$10M Buy
70,593
+3,327
+5% +$471K 0.09% 212
2021
Q3
$8.8M Buy
67,266
+1,812
+3% +$237K 0.08% 232
2021
Q2
$8.99M Buy
65,454
+3,666
+6% +$502K 0.09% 229
2021
Q1
$8.07M Sell
61,788
-674
-1% -$81.1K 0.08% 240
2020
Q4
$7M Sell
62,462
-1,134
-2% -$107K 0.08% 238
2020
Q3
$5M Buy
63,596
+51,738
+436% +$4.22M 0.07% 262
2020
Q2
$853K Buy
11,858
+5,362
+83% +$373K 0.01% 475
2020
Q1
$372K Buy
+6,496
New +$599K 0.01% 637

Other funds holding CNMD

Segall Bryant & Hamill's CNMD Position: Q1 2026 in Review

Segall Bryant & Hamill sold out of CONMED (CNMD) in Q1 2026, closing a stake of 41,558 shares — an estimated $1.69M sold.

Segall Bryant & Hamill first reported a position in CNMD in Q1 2020 and held it in 19 quarters. The position peaked at $11.2M in Q4 2022. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • Segall Bryant & Hamill reported no remaining CONMED position as of Q1 2026 after selling out during the quarter.
  • Segall Bryant & Hamill sold 41,558 CONMED shares in Q1 2026, an estimated $1.69M.
  • Segall Bryant & Hamill first reported a position in CONMED in Q1 2020 and held it in 19 quarters.
  • Segall Bryant & Hamill's CONMED position peaked at $11.2M in Q4 2022.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.